Hepion Pharmaceuticals Secures $9 Million in Funding for Groundbreaking Liver Disease Therapy CRV431

Hepion Pharmaceuticals (Nasdaq: HEPA) is excited to announce that it has successfully raised $9 million in a recent funding round, marking a significant milestone in the company’s mission to transform the treatment landscape for chronic liver diseases. Specializing in the development of pleiotropic drug therapy, Hepion is pioneering innovative solutions for conditions such as non-alcoholic steatohepatitis (NASH), viral hepatitis, and hepatocellular carcinoma (HCC). The funds will primarily be utilized to advance the clinical development of Hepion's leading candidate, CRV431, a cyclophilin inhibitor designed to target the multiple biochemical pathways involved in liver disease progression. Preclinical studies have shown that CRV431 consistently reduces liver inflammation, fibrosis, and even cancerous tumors, while also exhibiting antiviral activity against hepatitis B, C, and D viruses. The promising results from Phase 1 human clinical trials, which demonstrated good safety and tolerability, reinforce our belief in CRV431's potential. With funding now secured, Hepion is poised to enhance its clinical trials and further explore the drug's efficacy, inevitably paving the way for new therapeutic opportunities that could alleviate the life-threatening risks associated with liver disease. This funding will not only help in executing our strategic plans but also exemplifies investor confidence in our mission to address one of the most critical areas in healthcare today. Hepion remains committed to fighting chronic liver diseases and improving outcomes for patients worldwide.